HW
BMRN icon

Hancock Whitney’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hancock Whitney’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,398
Closed -$209K – 610
2024
Q1 		$209K Hold
2,398
– – 0.01% 612
2023
Q4 		$231K Hold
2,398
– – 0.01% 595
2023
Q3 		$212K Hold
2,398
– – 0.01% 587
2023
Q2 		$208K Sell
2,398
-132
-5% -$12.4K 0.01% 595
2023
Q1 		$246K Buy
2,530
+20
+0.8% +$2.07K 0.01% 575
2022
Q4 		$260K Hold
2,510
– – 0.01% 560
2022
Q3 		$213K Hold
2,510
– – 0.01% 581
2022
Q2 		$208K Buy
+2,510
New +$200K 0.01% 608
2022
Q1 		– Sell
-2,510
Closed -$222K – 690
2021
Q4 		$222K Sell
2,510
-80
-3% -$6.6K 0.01% 649
2021
Q3 		$200K Sell
2,590
-458
-15% -$36.1K 0.01% 652
2021
Q2 		$254K Buy
3,048
+69
+2% +$5.47K 0.01% 717
2021
Q1 		$225K Sell
2,979
-461
-13% -$37.7K 0.01% 716
2020
Q4 		$302K Sell
3,440
-208
-6% -$16.5K 0.01% 642
2020
Q3 		$278K Sell
3,648
-72
-2% -$7.29K 0.01% 647
2020
Q2 		$459K Sell
3,720
-307
-8% -$30.5K 0.02% 527
2020
Q1 		$340K Buy
4,027
+92
+2% +$7.93K 0.01% 600
2019
Q4 		$333K Sell
3,935
-899
-19% -$67.9K 0.01% 657
2019
Q3 		$326K Sell
4,834
-146
-3% -$11.2K 0.01% 676
2019
Q2 		$427K Sell
4,980
-116
-2% -$9.92K 0.01% 650
2019
Q1 		$453K Sell
5,096
-1,357
-21% -$126K 0.01% 643
2018
Q4 		$549K Sell
6,453
-453
-7% -$43.1K 0.02% 545
2018
Q3 		$670K Buy
+6,906
New +$689K 0.02% 575

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Hancock Whitney's BMRN Position: Q2 2024 in Review

Hancock Whitney sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 2,398 shares — an estimated $209K sold.

Hancock Whitney first reported a position in BMRN in Q3 2018 and held it in 22 quarters. The position peaked at $670K in Q3 2018. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Hancock Whitney reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Hancock Whitney sold 2,398 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $209K.
  • Hancock Whitney first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 22 quarters.
  • Hancock Whitney's BioMarin Pharmaceuticals position peaked at $670K in Q3 2018.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Hancock Whitney's 13F filing for Q2 2024, filed 13 Aug 2024.